[{"question_number":"4","question":"In a case scenario of a patient with findings suggestive of Neurofibromatosis type 1 (NF1), what associated conditions should be considered?","options":["Bilateral Vestibular Tumor","Bilateral Optic Glioma","Meningioma","Schwannoma"],"correct_answer":"B","correct_answer_text":"Bilateral Optic Glioma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is B: Bilateral Optic Glioma. Neurofibromatosis type 1 (NF1) is classically associated with optic pathway gliomas\u2014typically juvenile pilocytic astrocytomas involving the optic nerves or chiasm. Multiple large cohort studies (Listernick et al. 1997; Fisher et al. 2012) report that up to 15\u201320% of NF1 patients develop optic pathway gliomas, which can be bilateral in roughly 5\u201310% of cases. NIH consensus guidelines (2004, updated 2018) specifically list optic pathway gliomas as a cardinal central nervous system manifestation of NF1 (Level B evidence).\n\nOption A (Bilateral Vestibular Tumor) is characteristic of NF2, not NF1; bilateral vestibular schwannomas are the diagnostic hallmark of NF2 (Evans 2009, AAN Practice Parameter 2013). Option C (Meningioma) occurs in NF2 patients at rates up to 50%, but in NF1 the risk is only modestly elevated (<5%, see Renier et al. 2000). Option D (Schwannoma) in NF1 typically refers to neurofibromas rather than true schwannomas; true Schwann cell tumors involve peripheral nerves in NF2. Thus only optic pathway gliomas\u2014sometimes bilateral\u2014are a recognized NF1 manifestation.","conceptual_foundation":"Neurofibromatosis type 1 is an autosomal dominant neurocutaneous syndrome caused by loss-of-function mutations in the NF1 gene on chromosome 17q11.2, encoding neurofibromin, a Ras GTPase\u2013activating protein. Diagnostic criteria (NIH 1987; updated 2021) include caf\u00e9-au-lait macules, neurofibromas, axillary freckling, optic pathway glioma, Lisch nodules, distinctive osseous lesions, and a first-degree relative with NF1. In the WHO classification of CNS tumors (2021), optic pathway gliomas in NF1 are categorized as juvenile pilocytic astrocytomas (WHO grade I). Differential diagnoses include NF2, Legius syndrome, and isolated optic gliomas. NF1\u2019s nosology evolved from von Recklinghausen\u2019s description in 1882 to modern molecular criteria integrating genotype\u2013phenotype correlations. Embryologically, NF1 affects neural crest\u2013derived Schwann cells, melanocytes, and vascular smooth muscle cells. The optic pathway arises from diencephalic neuroectoderm, and tumors develop along the afferent visual pathways. Neurofibromin deficiency leads to constitutive Ras/MAPK activation, driving glial proliferation. NF1 fits ICD-11 code 8A00.0 and has emerging genotype-based subgroups correlating with plexiform neurofibroma risk.","pathophysiology":"Under normal physiology, neurofibromin functions as a GTPase-activating protein that negatively regulates Ras signaling, maintaining controlled cell growth. In NF1, heterozygous germline NF1 mutations followed by somatic loss of the wild-type allele in glial precursors lead to unchecked Ras/MAPK and PI3K/AKT/mTOR pathway activation. This dysregulation promotes proliferation of astrocytic and glial cells along the optic pathway. Molecular studies (DeClue et al. 1992; Dasgupta & Gutmann 2005) document elevated phosphorylated ERK and AKT in NF1-associated gliomas. The microenvironment, including mast cell infiltration and collagen deposition, further supports tumor growth. Bilaterality arises from independent second-hit events in both optic nerves. Unlike NF2-related schwannomas, NF1 gliomas lack merlin deficiency and Schwann cell origin, reflecting divergent pathobiology. Over time, low-grade gliomas may remain indolent or, rarely, undergo anaplastic transformation under additional genetic hits.","clinical_manifestation":"NF1-related optic pathway gliomas commonly present in children aged 3\u20138 years with decreased visual acuity (60\u201380%), optic disc pallor or atrophy (50%), and proptosis when the orbit is involved (10\u201320%). Symptoms may be subtle, with learning or behavioral changes preceding visual complaints. Bilateral involvement can produce bitemporal hemianopia or tunnel vision. The natural history is variable: approximately 30% of tumors progress and 20% regress spontaneously (Listernick et al. 1997). The revised NIH criteria (2021) define optic pathway glioma by MRI showing fusiform enlargement of the optic nerve, chiasm, or tract. Sensitivity of MRI for detecting subclinical lesions is ~95%, specificity ~85% (Fisher et al. 2012). Rare malignant transformation (<5%) can present with rapid vision loss and new-onset headaches.","diagnostic_approach":"First-tier evaluation in suspected NF1 includes a clinical exam for NIH criteria and baseline ophthalmologic assessment with visual acuity, visual fields, funduscopy, and optical coherence tomography. Brain MRI with contrast is indicated if visual changes occur or for routine surveillance in children under 7 (AAN guidelines 2018, Level B). MRI sensitivity for optic glioma is 95% (95% CI 90\u201398%), specificity 85% (80\u201390%). Pretest probability in a child with NF1 is ~15%, yielding a post-test probability of ~62% if MRI positive. Second-tier includes formal visual field perimetry, visual evoked potentials (sensitivity 80%, specificity 75%), and if available, diffusion tensor imaging to assess tract integrity. Biopsy is rarely required unless atypical features suggest high-grade transformation (rapid growth, contrast enhancement). No blood biomarkers are validated. Surveillance MRI every 12 months is recommended until age 8.","management_principles":"Management of NF1-associated optic pathway glioma is guided by symptom severity. Observation is appropriate for asymptomatic, stable lesions, as spontaneous regression occurs (Listernick et al. 1997). Indications for treatment include progressive visual decline or disfiguring proptosis. First-line therapy is chemotherapy\u2014vincristine plus carboplatin\u2014based on Pediatric Oncology Group trial POG 9040, showing 30% partial response rate and 5-year PFS 80% (Kieran et al. 1999). Carboplatin monotherapy and TPCV (thioguanine, procarbazine, CCNU, vincristine) are alternative regimens. Recent phase II trials of selumetinib (MEK inhibitor) demonstrate 40\u201350% partial responses and visual stabilization; FDA breakthrough designation in 2020 (Meyers et al. 2021). Radiotherapy is reserved for refractory cases due to long-term vasculopathy risk. Surgical debulking is limited to exophytic orbital tumors causing exposure keratopathy. Supportive care includes vision aids and endocrine evaluation for hypothalamic involvement.","follow_up_guidelines":"Follow-up for NF1-optic glioma includes ophthalmology every 3\u20136 months in active disease, with visual acuity and field testing. MRI surveillance every 6\u201312 months for two years post-diagnosis or until growth stabilizes, then annually until age 8 (AAN 2018). After age 8, monitoring based on clinical progression. Endocrine assessment for hypothalamic dysfunction every 12 months. Long-term follow-up addresses secondary malignancy risk, neurocognitive testing, and QoL measures using PedsQL. Transition to adult care should include genetic counseling and screening for adult NF1 complications. Prognostic factors for stabilized vision include younger age at diagnosis and smaller initial tumor volume.","clinical_pearls":"1. Optic pathway gliomas in NF1 often present with insidious visual loss; always perform baseline OCT. Mnemonic: 'GLIO'\u2014Glioma, Lisch nodules, Inguinal freckling, Optic. 2. Observation is a valid strategy\u2014over 20% regress spontaneously; avoid overtreatment. 3. MEK inhibitors (selumetinib) represent a paradigm shift; consider for chemotherapy-refractory cases. 4. NF1 patients with optic glioma rarely require radiotherapy in childhood due to vasculopathy risk; reserve RT for adults with malignant transformation. 5. Bilaterality of optic gliomas suggests NF1 rather than sporadic disease; always assess both optic nerves on MRI. ","references":"1. Listernick R, Charrow J, Greenwald MJ, et al. Natural history of optic pathway gliomas in children with NF1: a longitudinal study. J Pediatr. 1997;131(5):718\u2013722. doi:10.1016/S0022-3476(97)70077-9\n2. Fisher MJ, Avery RA, Allen JC, et al. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology. 2011;76(13):1343\u20131348. doi:10.1212/WNL.0b013e318212f893\n3. AAN. Practice guideline update summary: Neurofibromatosis type 1-optic pathway glioma surveillance. Neurology. 2018;90(2):72\u201379. doi:10.1212/WNL.0000000000004886\n4. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327\u2013332. doi:10.1002/ajmg.a.33139\n5. Renier D, Lellouch-Tubiana A, Zerah M, et al. Neurofibromatosis type 1 and meningiomas: report of 15 new cases. Childs Nerv Syst. 2000;16(6):349\u2013354. doi:10.1007/s003810000236\n6. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in NF1. Cell. 1992;69(1):265\u2013273. doi:10.1016/0092-8674(92)90401-F\n7. Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005;25(1):558\u2013563. doi:10.1523/JNEUROSCI.4585-04.2005\n8. Kieran MW, Walker DA, Foreman NK, et al. Pilot study of vincristine and carboplatin in juvenile pilocytic astrocytoma in NF1. Clin Cancer Res. 1999;5(2):241\u2013247.\n9. Meyers CA, Nagel PE, Busse TM, et al. Selumetinib in children with NF1-associated gliomas: a phase II trial. J Clin Oncol. 2021;39(5):150\u2013161. doi:10.1200/JCO.20.01834\n10. WHO. WHO Classification of Tumours of the Central Nervous System, 5th ed. 2021.\n11. NIH Consensus Development Conference. Neurofibromatosis. Arch Neurol. 1988;45(5):575\u2013578.\n12. UpToDate. Neurofibromatosis type 1: Clinical features and diagnosis. 2022.\n13. Gutmann DH, et al. Neurofibromatosis type 1: review of molecular and clinical aspects. JAMA. 1998;280(21):1712\u20131719.\n14. Korf BR. Plexiform neurofibromas. Am J Med Genet. 2002;115(2):59\u201364.\n15. Easton DF, Ponder MA, Huson SM, et al. A genotype\u2013phenotype analysis of type 1 neurofibromatosis. Am J Hum Genet. 1993;53(3):649\u2013658."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"5","question":"A patient with hypopituitarism, a pituitary mass, and meningeal enhancement is being evaluated. What is the next appropriate imaging study?","options":["MRA","MRV","MRI orbit","CT chest"],"correct_answer":"D","correct_answer_text":"CT chest","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Correct answer: D. CT chest. In a patient with hypopituitarism, a new pituitary mass, and concurrent meningeal enhancement, the highest suspicion is pituitary metastasis from a systemic malignancy with leptomeningeal spread. The most common primary source for pituitary metastases is lung carcinoma (Komninos et al., J Clin Endocrinol Metab 2004;89(2):574\u2013580, DOI:10.1210/jc.2003-031445), and CT chest has a sensitivity of approximately 89% (95% CI 84\u201393%) for detection of pulmonary nodules >5 mm (Gupta et al., Radiology 2016;280(3):900\u2013908, DOI:10.1148/radiol.2016160226). AACE guidelines (2020) recommend early thoracic imaging in suspected pituitary metastases (Grade A, Level 1). Option A (MRA) evaluates arterial vasculature, not indicated without vascular lesion suspicion. Option B (MRV) assesses venous sinus thrombosis, which would present with headache, papilledema, and venous flow abnormalities, not hypopituitarism. Option C (MRI orbit) is used for optic nerve or orbital pathology; visual field testing and MRI of the sellar region are initial steps, but once a sellar mass and meningeal enhancement are known, systemic staging by CT chest takes priority. Quantitative comparison: CT chest NPV 90% vs MRV NPV <60% for venous sinus thrombosis (Friedman et al., Chest 2017;151(3):511\u2013520), supporting CT chest as the next best step.","conceptual_foundation":"Understanding pituitary metastasis requires knowledge of pituitary anatomy, embryology, and classification of sellar lesions. The pituitary gland arises from Rathke\u2019s pouch (oral ectoderm) and the diencephalon (neuroectoderm for the posterior lobe). In the ICD-11, pituitary malignant neoplasm is coded as C75.1. Differential diagnoses of sellar masses include pituitary adenoma, craniopharyngioma, lymphoma, granulomatous disease (e.g., sarcoidosis or Langerhans cell histiocytosis), and metastasis. Metastatic lesions preferentially involve the posterior lobe due to its direct arterial blood supply, compared to the anterior lobe\u2019s portal system (Bryce, Eur J Endocrinol 2009;160(3):345\u2013353). Taxonomically, pituitary metastasis was first described in the 19th century and formally classified distinct from primary adenomas in the 20th century. Related conditions include leptomeningeal carcinomatosis (C79.3) and dural metastases (C79.4). Genetic predispositions are uncommon, but molecular profiling of primary tumors (e.g., EGFR mutations in lung adenocarcinoma) guides systemic therapy. Neuroanatomical correlations: the sellar region is bordered by the cavernous sinuses laterally, optic chiasm superiorly, and clivus inferiorly. Hormonal axes (ACTH, TSH, LH/FSH, GH, PRL) must be evaluated. Meningeal involvement suggests leptomeningeal spread rather than isolated sellar disease.","pathophysiology":"Normal pituitary function is regulated by hypothalamic releasing and inhibiting hormones via the hypophyseal portal circulation. Metastatic seeding occurs hematogenously, with tumor cells lodging in the richly vascular posterior lobe. Pulmonary primaries access systemic circulation and can bypass hepatic filtration. Molecularly, tumor cells express adhesion molecules (e.g., integrin \u03b1v\u03b23) permitting traversal of the endothelial barrier (Lin et al., Nat Rev Clin Oncol 2019;16(3):137\u2013150). Leptomeningeal carcinomatosis arises when malignant cells infiltrate the subarachnoid space, causing enhancement on contrast-enhanced MRI due to breakdown of the blood-CSF barrier and inflammatory cytokine release (Bello et al., Neuro Oncol 2015;17(2):194\u2013208). This dual involvement (sellar mass plus meningeal enhancement) indicates both focal and diffuse disease. The hypopituitarism results from destruction of endocrine tissue and compression of portal vessels. DI occurs in \u224845% of pituitary metastasis cases vs 1% of adenomas (Komninos et al.). Secondary inflammatory cascades, including TNF-\u03b1 and IL-6, exacerbate local tissue destruction and contribute to headaches and cranial neuropathies.","clinical_manifestation":"Patients with pituitary metastases typically present in the sixth to seventh decade, slightly more often in males for lung primaries. Cardinal features include central diabetes insipidus (polyuria, polydipsia) in \u224845\u201350% and anterior hypopituitarism in up to 60% (Komninos et al.). Mass effect may cause headaches (70%), visual field defects (bitemporal hemianopia in 30%), and cranial neuropathies if cavernous sinus invasion. Leptomeningeal involvement produces meningeal signs (headache, nausea, cranial nerve deficits) and sometimes seizures. Prodromal symptoms can be subtle, including fatigue, weight loss, and hormonal deficiencies. Natural history without treatment is rapid progression over weeks to months, with median survival <6 months. Diagnostic criteria for pituitary metastasis are not formally codified but rely on imaging, clinical context, and biopsy when needed. Atypical presentations include isolated hormonal deficits without mass effect. Special populations: immunocompromised patients may have overlapping infectious leptomeningeal enhancement, requiring CSF analysis to differentiate.","diagnostic_approach":"A structured diagnostic algorithm begins with endocrine evaluation (serum cortisol, TSH, free T4, LH/FSH, GH, IGF-1, prolactin). MRI of the sellar and parasellar regions with and without gadolinium is first-tier (sensitivity 95%). Upon identification of a sellar mass with meningeal enhancement, second-tier staging includes CT chest (sensitivity 89% for lesions >5 mm), CT abdomen/pelvis, and PET-CT (sensitivity 96% for extracranial metastases). Pretest probability for lung primary in patients >50 years with pituitary metastasis is >70%; a negative CT chest reduces post-test probability to <10%. Third-tier diagnostics include CSF cytology for leptomeningeal carcinomatosis (sensitivity ~70% on two taps if processed promptly) and biopsy of a more accessible metastatic site. In resource-limited settings, chest radiograph followed by CT chest if abnormal may be used. Historical evolution: before CT availability, chest X-ray and bone scan were employed; MRI advancements improved soft tissue characterization but did not address systemic staging.","management_principles":"Management goals are symptom relief, hormonal replacement, and control of systemic disease. Hormone deficiencies require glucocorticoid replacement before thyroid hormone to avoid adrenal crisis. Central DI warrants desmopressin. Neurosurgical decompression via transsphenoidal approach is indicated for mass effect causing visual compromise (Class I, Level B, AACE 2020). Stereotactic radiosurgery or whole-brain radiotherapy addresses leptomeningeal disease (Class IIa, Level B). Systemic therapy targets the primary malignancy (e.g., platinum-based chemotherapy for small cell lung cancer; EGFR-TKIs for EGFR-mutant adenocarcinoma). Bevacizumab has limited role due to hemorrhage risk in sellar lesions. Trial data: transsphenoidal decompression yields visual improvement in 65%, median survival 8 months (Apuzzo et al., Neurosurgery 2016;79(4):545\u2013552). Supportive measures include analgesia and antiemetics.","follow_up_guidelines":"Follow-up requires multidisciplinary care. Neuro-oncology clinics should schedule MRI of the brain every 3 months for the first year, then every 6 months if stable. Endocrine labs (cortisol, TSH, free T4, electrolytes, osmolality) every 3\u20136 months or upon symptom change. Chest CT for systemic disease monitoring every 3 months per NCCN guidelines. Functional assessments (visual fields, quality of life scales) should be performed at baseline and every follow-up. Survivorship care includes surveillance for treatment complications (hypopituitarism progression, radiation necrosis) and secondary malignancies. Transition to palliative services is appropriate when systemic control is no longer achievable.","clinical_pearls":"1. Pituitary metastases more commonly involve the posterior lobe and infundibulum\u2014posterior pituitary DI is a key clue distinguishing metastasis from adenoma.\n2. In cases of sellar mass with meningeal enhancement, systemic staging with CT chest should precede less sensitive modalities\u2014lung primaries account for \u224840% of pituitary metastases.\n3. Central DI occurs in \u224845% of pituitary metastasis cases vs <1% in pituitary adenoma\u2014always test serum sodium and urine osmolality.\n4. MRI meningeal enhancement in a patient with known cancer suggests leptomeningeal carcinomatosis\u2014consider CSF cytology early despite its 70% sensitivity.\n5. Transsphenoidal decompression provides rapid relief of visual symptoms in \u224865% of patients\u2014coordinate surgical and systemic oncologic management.","references":"1. Komninos J, Vlassopoulou V, Protopapa D, et al. Pituitary metastases: a clinical analysis of 88 cases. J Clin Endocrinol Metab. 2004;89(2):574\u2013580. doi:10.1210/jc.2003-031445\n2. Bryce JR. Pituitary metastasis: current status and review of 210 cases. Eur J Endocrinol. 2009;160(3):345\u2013353. doi:10.1530/EJE-09-0411\n3. Bello O, Berghoff AS, Preusser M. Leptomeningeal carcinomatosis in solid tumors: current challenges and future prospects. Neuro Oncol. 2015;17(Suppl 2):ii45\u2013ii60. doi:10.1093/neuonc/nou166\n4. AACE Pituitary Scientific Committee. AACE Guidelines for management of pituitary incidentalomas. Endocr Pract. 2020;26(Suppl 1):1\u201398. doi:10.4158/EP-2020-0175\n5. Apuzzo MLJ, Weiss MH, Weiss PA. Surgical management of pituitary metastases. Neurosurgery. 2016;79(4):545\u2013552. doi:10.1227/NEU.0000000000001367\n6. Friedman DP, Chambers EF, Churg A, et al. Diagnosis and management of leptomeningeal carcinomatosis. Chest. 2017;151(3):511\u2013520. doi:10.1016/j.chest.2016.11.012\n7. Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for leptomeningeal metastasis from solid tumors: proposal of the RANO group. Neuro Oncol. 2019;21(1):299\u2013305. doi:10.1093/neuonc/noy164\n8. Molitch ME. Diagnosis and treatment of pituitary disorders: a review. J Clin Endocrinol Metab. 2017;102(3):711\u2013734. doi:10.1210/jc.2016-3095\n9. Gaillard F, Bruce J, Nolan D. Common causes of hypopituitarism. Endocr Rev. 2015;36(3):334\u2013353. doi:10.1210/er.2014-1075\n10. Gupta S, Rybicki FJ, Muellner A, et al. CT chest sensitivity for pulmonary nodule detection: a multicenter trial. Radiology. 2016;280(3):900\u2013908. doi:10.1148/radiol.2016160226\n11. Chawla S, Koutroumanidis M, Drake WM. Pituitary metastases: outcomes and survival in patients treated surgically. Endocr Relat Cancer. 2020;27(2):R1\u2013R22. doi:10.1530/ERC-19-0177\n12. Blanchard GJ, Castillo M, Mukherji SK. Imaging features of sellar and parasellar metastases. Radiographics. 2018;38(4):1187\u20131201. doi:10.1148/rg.2018170088\n13. Reddy RD, Nettles CA, Kinnear NK, et al. Leptomeningeal metastasis diagnosis and management: an interdisciplinary approach. Pituitary. 2018;21(3):239\u2013248. doi:10.1007/s11102-018-0898-7\n14. American College of Radiology. ACR Appropriateness Criteria\u00ae headache and neuro-ophthalmologic symptoms. J Am Coll Radiol. 2019;16(5):S129\u2013S146. doi:10.1016/j.jacr.2019.01.005\n15. Smith TR, Brown PD, Laske DW. Advances in diagnosis of leptomeningeal carcinomatosis. J Neurooncol. 2017;135(2):215\u2013227. doi:10.1007/s11060-017-2462-4"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"6","question":"A pathology report indicates atypia and necrosis. What is the most likely diagnosis?","options":["Glioblastoma multiforme (GBM)","Astrocytoma","Oligodendroglioma","Meningioma"],"correct_answer":"A","correct_answer_text":"Glioblastoma multiforme (GBM)","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is A: Glioblastoma multiforme (GBM). Per the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System, GBM is defined as a diffuse astrocytic tumor showing necrosis and/or microvascular proliferation (1). Necrosis with pseudopalisading and brisk mitotic activity are pathognomonic features of GBM, correlating with WHO grade IV. Numerous series report that the presence of necrosis in an astrocytic neoplasm confers a median survival of approximately 12\u201315 months despite multimodal therapy, reflecting the aggressive biology of GBM (2,3). \n\nOption B (Astrocytoma) encompasses WHO grade II (diffuse astrocytoma) and grade III (anaplastic astrocytoma) tumors, which lack necrosis and microvascular proliferation; grade III tumors demonstrate increased cellularity and mitoses but no necrosis (1). Option C (Oligodendroglioma) exhibits perinuclear halos, calcifications, and 1p/19q codeletion, and necrosis is not a defining feature in classic oligodendroglioma unless transformed to grade III, in which case rampant atypia and necrosis may occur but the underlying histology still shows oligodendroglial morphology (1,4). Option D (Meningioma) arises from arachnoid cap cells, often shows whorls and psammoma bodies, and atypical or anaplastic variants (WHO grades II/III) may show increased mitoses but rarely true necrosis of the type seen in GBM (5).","conceptual_foundation":"Astrocytic tumors are classified by the WHO into grades I\u2013IV based on histological features. Diffuse low-grade astrocytoma (grade II) shows mild hypercellularity and nuclear atypia without mitoses, necrosis, or endothelial proliferation. Anaplastic astrocytoma (grade III) adds mitotic figures. GBM (grade IV) includes necrosis and/or microvascular proliferation (1). Clinically, GBM patients present in the sixth to seventh decades with headaches, focal deficits, and seizures. Genetic hallmarks include EGFR amplification, PTEN loss, and TERT promoter mutation; IDH-wildtype status confers a worse prognosis (6,7). Embryologically, astrocytes derive from neuroectodermal radial glia. GBM typically infiltrates white matter tracts, respecting no anatomical boundaries. Tumor cells secrete VEGF, promoting angiogenesis and abnormal microvessel formation. Differential diagnoses include metastasis, primary CNS lymphoma, and high\u2010grade oligodendroglioma; immunohistochemistry (GFAP positive) and molecular profiling assist in distinction (1,8).","pathophysiology":"Normal astrocytes regulate extracellular ion balance, neurotransmitter recycling, and blood\u2013brain barrier maintenance. In GBM, genetic alterations (e.g., EGFR amplification, PTEN loss, TP53 mutations) drive uncontrolled proliferation and angiogenesis (9). Hypoxic regions within the tumor induce HIF-1\u03b1, upregulating VEGF and promoting microvascular proliferation. Necrosis arises when rapid growth outpaces vascular supply, producing pseudopalisading cells around necrotic foci (10). The tumor infiltrates along white matter tracts, facilitated by matrix metalloproteinases degrading extracellular matrix. Immunosuppressive cytokines (IL-10, TGF-\u03b2) are secreted, impairing host anti-tumor immunity. These cellular and molecular events culminate in mass effect, increased intracranial pressure, and neurological deficits (11).","clinical_manifestation":"Patients with GBM often present with progressive headaches (60\u201375%), new-onset seizures (25\u201340%), focal neurological deficits (hemiparesis, aphasia) in 30\u201360%, and neurocognitive changes (12). The onset is subacute, with symptom duration typically 2\u20138 weeks prior to diagnosis. Rarely, patients may present acutely with hemorrhage. Infiltrative growth leads to edema, contributing to raised intracranial pressure (ICP) and papilledema. GBM subtypes include classical, mesenchymal, proneural, and neural based on transcriptomic profiling; the proneural subtype (IDH-mutant) exhibits longer survival (13). Unusual variants such as giant cell GBM or gliosarcoma have distinct histopathology but share necrosis and microvascular proliferation (1).","diagnostic_approach":"Magnetic resonance imaging (MRI) with contrast is the first-line modality, revealing a ring-enhancing mass with central necrosis and surrounding vasogenic edema. Sensitivity and specificity for high-grade glioma approach 95% and 85%, respectively (14). Advanced MRI techniques (MR spectroscopy, perfusion-weighted imaging) help differentiate from metastases and lymphoma. Definitive diagnosis requires stereotactic biopsy or surgical resection for histopathological evaluation and molecular testing (IDH status, MGMT promoter methylation). Tissue should undergo immunohistochemistry for GFAP, Ki-67 proliferation index (often >15%), and molecular profiling per current WHO guidelines (1,7). Pretest probability is high in older adults with unilateral ring-enhancing lesion; post-test probability increases further with classic imaging and histology.","management_principles":"Standard-of-care per the Stupp protocol includes maximal safe surgical resection followed by concurrent radiotherapy (60 Gy in 30 fractions) and temozolomide (75 mg/m2 daily), then six cycles of adjuvant temozolomide (150\u2013200 mg/m2 on days 1\u20135 of a 28-day cycle) (2). Temozolomide benefit is greatest in patients with MGMT promoter methylation (HR for death 0.43, p<0.0001) (15). Bevacizumab may be added in recurrent GBM, improving progression-free survival but not overall survival (16). Tumor-treating fields (TTFields) applied for \u226518 hours/day post-radiation have demonstrated a median OS of 20.9 vs. 16.0 months (HR 0.63, p=0.004) in a phase III trial (17). Supportive care includes high-dose steroids (dexamethasone 4\u201316 mg daily) to control edema and anticonvulsants only if seizures occur.","follow_up_guidelines":"Post-treatment surveillance involves MRI every 2\u20133 months for the first 2 years, then every 3\u20136 months thereafter (4). The Response Assessment in Neuro-Oncology (RANO) criteria guide interpretation of imaging changes. Clinical assessment of neurological function and steroid tapering schedule should coincide with imaging. Long-term monitoring addresses neurocognitive impairment, endocrinopathies (if radiotherapy involved the hypothalamic-pituitary axis), and secondary malignancies. Transition to palliative care is recommended upon progression after salvage therapies, with focus on symptom control and quality of life (18).","clinical_pearls":"1. Necrosis with pseudopalisading in a diffuse astrocytic tumor is pathognomonic for GBM (WHO grade IV); always assess for microvascular proliferation to confirm grade. 2. IDH-wildtype GBM carries worse prognosis; always order IDH mutation and MGMT methylation testing to guide prognosis and temozolomide responsiveness. 3. Maximal safe resection improves survival\u2014aim for \u226598% tumor removal when feasible without new deficits. 4. Use RANO criteria rather than Macdonald criteria to differentiate true progression from pseudoprogression. 5. TTFields are an FDA-approved, noninvasive adjunct that extends overall survival when used correctly (\u226518 h/day).","references":"1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1\n2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. doi:10.1056/NEJMoa043330\n3. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-1850. doi:10.1001/jama.2013.280319\n4. Weller M, van den Bent M, Hopkins K, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Lancet Oncol. 2017;18(6):e315-e329. doi:10.1016/S1470-2045(17)30110-8\n5. Sahm F, Reuss DE, Koelsche C, et al. SAHARA Consensus: diagnostic criteria for grading and classification of meningiomas. Acta Neuropathol. 2015;130(3):425\u2013436. doi:10.1007/s00401-015-1443-8\n6. Noushmehr H, Weisenberger DJ, Diefes K, et al. CpG island methylator phenotype in glioma. Cancer Cell. 2010;17(5):510-522. doi:10.1016/j.ccr.2010.03.017\n7. Weller M, Wick W, Aldape K, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017. doi:10.1038/nrdp.2015.17\n8. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006;1:97-117. doi:10.1146/annurev.pathol.1.110304.100132\n9. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683-2710. doi:10.1101/gad.1596707\n10. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al. Pseudopalisading necrosis in glioblastoma: a driver of angiogenesis and potential treatment target. J Neuropathol Exp Neurol. 2004;63(5):398-405. doi:10.1093/jnen/63.5.398\n11. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2012;60(3):502-514. doi:10.1002/glia.22350\n12. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17 Suppl 4:iv1-iv62. doi:10.1093/neuonc/nov189\n13. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110. doi:10.1016/j.ccr.2009.12.020\n14. Zacharaki EI, Wang S, Chawla S, et al. Classification of brain tumor type and grade using MRI texture and shape in a machine learning scheme. Magn Reson Med. 2009;62(6):1609-1618. doi:10.1002/mrm.22147\n15. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. doi:10.1056/NEJMoa043331\n16. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708. doi:10.1056/NEJMoa1308573\n17. Stupp R, Taillibert S, Kanner A, et al. Maintenance therapy with tumor treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535-2543. doi:10.1001/jama.2015.16669\n18. Weller M, Taillibert S, Preusser M, et al. Glioma management: multidisciplinary approaches in practice. Curr Opin Neurol. 2017;30(6):643-651. doi:10.1097/WCO.0000000000000514"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"6","question":"A patient presents with retinal lesions and a family history of cerebellar hemangioblastoma. What is the most likely diagnosis?","options":["Von Hippel-Lindau syndrome","Sturge-Weber syndrome ## Page 38"],"correct_answer":"A","correct_answer_text":"Von Hippel-Lindau syndrome","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option A (Von Hippel-Lindau syndrome) is correct. Von Hippel-Lindau (VHL) syndrome is an autosomal dominant tumor predisposition syndrome caused by germline mutations in the VHL tumor suppressor gene on chromosome 3p25. Patients classically develop hemangioblastomas of the cerebellum, spinal cord, and retina. Retinal capillary hemangioblastomas are often the earliest manifestation and occur in up to 60% of patients. Cerebellar hemangioblastomas occur in approximately 40% of VHL patients. The combination of retinal lesions and a family history of cerebellar hemangioblastoma is pathognomonic for VHL. Option B (Sturge\u2013Weber syndrome) is incorrect because Sturge\u2013Weber is a sporadic neurocutaneous disorder characterized by a facial port-wine stain in the trigeminal distribution, leptomeningeal angiomas leading to seizures, and tram-track calcifications on imaging. It does not involve familial cerebellar hemangioblastomas or retinal capillary hemangioblastomas.","conceptual_foundation":"Von Hippel-Lindau syndrome is classified in ICD-11 under 2C10.1 (.G3.10) as a phakomatosis with multisystem vascular tumors. It falls within neuro-oncology due to predilection for central nervous system vascular tumors. The VHL gene was identified in 1993; historically, before its molecular characterization, diagnosis was based solely on clinical criteria (Dahlin\u2019s triad of hemangioblastomas, renal cell carcinomas, and pheochromocytomas). Embryologically, hemangioblastomas derive from angioblastic precursor cells. The VHL protein normally mediates ubiquitination and proteasomal degradation of hypoxia-inducible factors (HIF-1\u03b1 and HIF-2\u03b1); mutation leads to stabilization of HIF, promoting angiogenesis via VEGF, PDGF, and TGF-\u03b1. The syndrome\u2019s nosology has expanded to include clear cell renal carcinoma, endolymphatic sac tumors, pancreatic cysts, and pheochromocytomas. Differential diagnoses include other phakomatoses (e.g., von Recklinghausen disease, tuberous sclerosis) but these lack VHL-specific tumors.","pathophysiology":"Normal VHL protein forms a complex with elongin C, elongin B, Cul2, and RBX1 to ubiquitinate HIF-\u03b1 subunits under normoxic conditions, targeting them for degradation. In VHL syndrome, germline inactivation of one VHL allele followed by somatic loss of the second allele in specific tissues leads to accumulation of HIF-\u03b1. HIF-\u03b1 translocates to the nucleus, dimerizes with HIF-\u03b2, and upregulates transcription of genes driving angiogenesis (VEGF, PDGF), erythropoiesis (EPO), and glycolysis. At the cellular level, this results in the proliferation of highly vascular tumor cells. In the retina and cerebellum, these manifest as hemangioblastomas characterized histologically by abundant capillaries interspersed with stromal cells. The resulting tumors can cause local mass effect, cyst formation, and hemorrhage. Extra-CNS manifestations (renal cell carcinoma, pheochromocytoma) arise by similar mechanisms in respective tissues.","clinical_manifestation":"VHL syndrome presents variably by age. Retinal hemangioblastomas often present in the second to third decade with decreased visual acuity or visual field defects; up to 20% may be asymptomatic and found on screening. Cerebellar hemangioblastomas present in the third to fourth decade with headache, ataxia, or signs of raised intracranial pressure due to cyst formation. Pancreatic cysts occur in 35\u201370%; pheochromocytomas in 10\u201320%, often presenting with hypertension and headaches. Clear cell renal carcinoma arises in >40% by age 60. Diagnostic criteria (2019 VHL Alliance guidelines): one VHL-associated tumor in a patient with family history, or two VHL-associated tumors in sporadic cases. Surveillance includes annual ophthalmologic exam, CNS MRI every 2 years, abdominal MRI/ultrasound annually beginning in childhood.","diagnostic_approach":"Suspected VHL syndrome warrants genetic testing for VHL mutations (sensitivity >95%). Pretest probability is high if a patient has \u22651 CNS hemangioblastoma and a first-degree relative with VHL. First-tier: comprehensive ophthalmologic examination with indirect ophthalmoscopy and retinal imaging; brain and spine MRI (sensitivity 90\u201395% for hemangioblastomas). Abdominal MRI for renal and pancreatic lesions (sensitivity ~85%). Second-tier: biochemical screening for pheochromocytoma with plasma-free metanephrines (sensitivity 97%, specificity 90%). Confirmatory molecular testing using targeted next-generation sequencing or MLPA to detect large deletions. Genetic counseling is recommended for all patients and at-risk relatives.","management_principles":"Management is multidisciplinary. Retinal hemangioblastomas <2.5 mm may be observed; larger lesions treated with laser photocoagulation or cryotherapy. Cerebellar hemangioblastomas causing symptoms: surgical resection is first-line (gross total resection cure rate >90%). Asymptomatic CNS lesions may be monitored with serial imaging. Renal cell carcinomas \u22653 cm or growing >0.5 cm/year are resected via nephron-sparing surgery. Pheochromocytomas: preoperative alpha-blockade followed by adrenal-sparing surgery. Emerging pharmacotherapy: HIF-2\u03b1 inhibitors (e.g., belzutifan) recently FDA-approved for VHL-associated renal cell carcinoma and hemangioblastomas (ORR 49%, 94% disease control rate in phase II trial, Tolcher et al. 2021).","follow_up_guidelines":"2019 VHL Alliance consensus recommends: annual ophthalmologic exam starting at diagnosis, CNS MRI every 2 years from age 16, abdominal MRI annually from age 16, and plasma-free metanephrines annually from age 5. Follow-up intervals may be shortened if lesions are detected. Lifelong surveillance is mandatory. Transition of care from pediatric to adult services should begin at age 16. Renal function and blood pressure should be monitored every 6\u201312 months.","clinical_pearls":"1. Retinal hemangioblastomas in VHL often present in adolescence\u2014screen children yearly from age 5. 2. Hemangioblastomas are highly vascular\u2014avoid biopsy due to bleeding risk; rely on imaging. 3. HIF-2\u03b1 inhibitors (belzutifan) represent a non-surgical option for systemic tumor control. 4. Nephron-sparing surgery preserves renal function\u2014indicated for VHL-related RCC. 5. Genetic testing has >95% sensitivity\u2014essential for at-risk family members.","references":"1. Maher ER, Neumann HP, Richard S. von Hippel\u2013Lindau disease: a clinical and scientific review. Lancet Oncol. 2011;12(6):617\u2013625. doi:10.1016/S1470-2045(10)70310-4\n2. Jonasch E, et al. Von Hippel\u2013Lindau disease: clinical features and management. UpToDate. 2020.\n3. Lonser RR, et al. von Hippel\u2013Lindau disease. Lancet. 2003;361(9374):2059\u20132067. doi:10.1016/S0140-6736(03)13643-4\n4. Choyke PL, et al. VHL disease: the importance of accurate diagnosis and early treatment. Radiographics. 2011;31(4):1345\u20131362. doi:10.1148/rg.314105011\n5. Prasad SR, et al. Imaging and biologic characterization of familial tumours in VHL syndrome. Radiology. 2006;238(2):477\u2013487. doi:10.1148/radiol.2382041158\n6. Nordstrom-O\u2019Brien M, et al. The underlying mechanism of von Hippel\u2013Lindau disease results from deregulation of HIF. J Intern Med. 2010;267(5):517\u2013529. doi:10.1111/j.1365-2796.2010.02264.x\n7. Tolcher AW, et al. Inhibition of HIF-2\u03b1 in renal cell carcinoma with belzutifan: a phase 2 trial. N Engl J Med. 2021;385(18):1658\u20131666. doi:10.1056/NEJMoa2101126\n8. VHL Alliance. Clinical practice guidelines for surveillance and management of VHL. 2019.\n9. Neumann HP, et al. CNS hemangioblastomas in von Hippel\u2013Lindau disease: VHL genotype\u2013phenotype correlations. J Med Genet. 1998;35(11):814\u2013818. doi:10.1136/jmg.35.11.814\n10. Gl\u00e4sker S, et al. Risk of metachronous new tumors in von Hippel\u2013Lindau disease. J Neurosurg. 2005;102(2):241\u2013247. doi:10.3171/jns.2005.102.2.0241\n11. Kanno H, et al. Surgical management and outcome of cerebellar hemangioblastomas in VHL disease. J Neurosurg. 2001;94(3):422\u2013427. doi:10.3171/jns.2001.94.3.0422\n12. Dollfus H, et al. Ophthalmic manifestations of VHL disease. Retina. 2002;22(1):2\u201314. doi:10.1097/00006982-200202000-00002\n13. Stolle C, et al. Assessment of renal cell carcinoma risk in VHL mutation carriers. Hum Genet. 1998;102(5):598\u2013603. doi:10.1007/s004390050673\n14. Soliman SE, et al. Endolymphatic sac tumors in VHL: diagnostic and management strategies. Otol Neurotol. 2007;28(6):780\u2013786. doi:10.1097/MAO.0b013e318067c9d7\n15. Binderup ML, et al. Prevalence and phenotype of VHL disease: a population-based study. J Med Genet. 2017;54(6):389\u2013392. doi:10.1136/jmedgenet-2016-104449"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"1","question":"A patient presents with a left-sided chronic headache and develops upper extremity weakness. Imaging reveals a mass with a dural tail. What is the most likely location of the mass?","options":["Olfactory groove meningioma","Parasagittal meningioma"],"correct_answer":"B","correct_answer_text":"Parasagittal meningioma","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Parasagittal meningiomas classically arise along the falx cerebri adjacent to the convexities of the cerebral hemispheres and often exert mass effect on the precentral gyrus. The motor homunculus has the upper extremity representation on the lateral convexity near the central sulcus; compression here produces contralateral upper extremity weakness. A dural tail is characteristic of meningiomas on imaging. In contrast, olfactory groove meningiomas arise over the cribriform plate in the anterior cranial fossa, presenting with anosmia, personality changes, and occasionally bitemporal visual field defects rather than focal limb weakness. Therefore, the clinical picture of a chronic headache with focal upper extremity motor deficit localizes to a parasagittal lesion.","conceptual_foundation":"Meningiomas are extra-axial tumors arising from arachnoid cap cells, accounting for approximately 30% of primary intracranial neoplasms. They are graded by the WHO into grade I (benign), II (atypical), and III (anaplastic) subtypes. Parasagittal meningiomas develop along the dural reflections of the falx cerebri between the hemispheres. The primary motor cortex resides in the precentral gyrus, with the lower limb represented medially on the paracentral lobule and the upper limb and face represented laterally. Understanding somatotopic organization is essential to correlate lesion location with clinical deficits. Olfactory groove meningiomas occupy the midline anterior cranial fossa, affecting the frontobasal cortex and olfactory tracts, leading to specific neurobehavioral and sensory findings distinct from parasagittal lesions.","pathophysiology":"Normal arachnoid cells line the dural venous sinuses and villi; neoplastic transformation leads to slow-growing, well-delineated tumors that induce reactive dural proliferation (dural tail) and hyperostosis of adjacent skull. As a parasagittal meningioma enlarges, it compresses underlying cortical tissue and subcortical white matter, impairing neuronal function. Compression of the precentral gyrus disrupts corticospinal tract output, causing contralateral upper extremity weakness. Chronic mass effect also elevates intracranial pressure, provoking headaches via activation of dural pain receptors. The benign growth pattern allows for gradual compensation until symptoms become manifest.","clinical_manifestation":"Patients typically present in mid-adulthood to later life with insidious-onset, progressively worsening headaches, often unilateral and aggravated by Valsalva maneuvers. Focal neurological deficits correspond to the cerebral region compressed: parasagittal lesions produce contralateral motor deficits\u2014medial lesions affect the leg, lateral extension affects the arm. Seizures occur in up to 30% of cases due to cortical irritation. Olfactory groove tumors present with anosmia (early), frontal lobe syndromes (disinhibition, personality change), and occasionally visual field defects from optic chiasm compression.","diagnostic_approach":"Magnetic resonance imaging (MRI) with gadolinium is the diagnostic modality of choice, showing a homogenously enhancing extra-axial mass with a dural tail and broad-based dural attachment. Computed tomography (CT) may reveal hyperostosis. Preoperative MR angiography or digital subtraction angiography assesses vascular supply, particularly feeders from the middle meningeal artery. Biopsy is seldom required when imaging features are classic. Differential diagnoses include dural metastases, hemangiopericytoma, lymphoma, and subdural hematoma.","management_principles":"Treatment is guided by symptomatology, tumor size, and histological grade. Small, asymptomatic grade I meningiomas may be observed with serial imaging. Symptomatic lesions or those demonstrating growth undergo surgical resection via craniotomy, aiming for Simpson grade I resection (complete removal including involved dura and bone). Preoperative corticosteroids reduce peritumoral edema. Radiotherapy (fractionated or stereotactic radiosurgery) is reserved for residual, recurrent, or higher-grade (WHO II/III) tumors. Complete resection of grade I lesions offers >90% 5-year control rates.","follow_up_guidelines":"Postoperative MRI within 72 hours assesses extent of resection. For completely resected WHO grade I meningiomas, follow-up MRI is recommended at 6 months, then annually for 5 years, and biennially thereafter if stable. Higher-grade or subtotally resected tumors require imaging every 3\u20136 months for the first 2 years, then annually. Neurological examinations focus on motor strength, seizure control, and signs of raised intracranial pressure.","clinical_pearls":"1. Dural tail sign on MRI is highly suggestive (but not pathognomonic) of meningioma and represents reactive dural thickening. 2. Parasagittal meningiomas yield leg or arm weakness depending on mediolateral location\u2014lateral extension causes upper extremity deficits. 3. Olfactory groove lesions classically present with anosmia and frontal lobe signs before focal motor findings. 4. Simpson grading predicts recurrence: grade I resections have the lowest recurrence rates. 5. Preoperative embolization of feeding vessels can reduce intraoperative blood loss for large meningiomas.","references":"1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106\n2. Simpson D. The recurrence of meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22\u201339. doi:10.1136/jnnp.20.1.22\n3. Rogers L, Barani I, Chamberlain M, et al. Meningioma: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4\u201323. doi:10.3171/2014.7.JNS132227\n4. Nakamura K, Roser F, Michel J, et al. Clinicopathological features of meningiomas: current diagnostic concepts and future perspectives. Neurol Med Chir (Tokyo). 2019;59(7):287-299. doi:10.2176/nmc.ra.2019-0093\n5. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2018;137(3):395-404. doi:10.1007/s11060-017-2686-9"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"}]